Youcare Pharmaceutical Group Co. Ltd. Class A
SSSE:68865812.30
CNY
-0.30
(-2.38%)
ISIN
CNE100005XQ2
Return %
Stock
S&P 500
1Y
-42.82
14.20
3Y
-28.86
81.12
5Y
-39.79
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Fei Yu
- Full Time Employees
- 2,870
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No.6 Middle Hongda Road Beijing BE China 100176
- IPO Date
- Dec 24, 2020
- Website
- youcareyk.com
- Similar Companies
- Business
- Youcare Pharmaceutical Group Co., Ltd. is a China-based pharmaceutical company primarily engaged in the research, development, manufacture, and sale of chemical drugs and biological pharmaceuticals. Its core product portfolio includes cardiovascular and cerebrovascular drugs, digestive system drugs, diabetes medications, and anti-infective agents, with key products such as ginkgo biloba extract injections, gastrodin injections, lansoprazole injections, omeprazole enteric-coated capsules, metformin hydrochloride sustained-release tablets, cefuroxime sodium injections, and ceftriaxone sodium injections. The company also extends its operations into innovative drug development focusing on nucleic acid drugs, peptides, cell therapies, small molecule drugs, and traditional Chinese medicine (TCM) innovations, covering over 200 pharmaceutical products across multiple therapeutic areas including oncology and infectious diseases. Founded in 2001 and headquartered in Beijing, Youcare operates predominantly within the Chinese market and has extended its reach to overseas markets. The company maintains advanced R&D platforms, including nucleic acid drug target discovery, peptide drug development, and controlled-release formulation technology platforms. It leverages national and local joint engineering laboratories and has established specialized research centers such as the Beijing Cardiovascular Engineering Research Center. Youcare's product dosage forms range widely across injections, freeze-dried powders, tablets, and capsules, supporting a comprehensive pharmaceutical industry chain from research and manufacturing to distribution and sales. In recent strategic developments, Youcare has secured multiple clinical trial approvals from the U.S. Food and Drug Administration for its innovative therapies, including a hypertension treatment candidate YKYY029 injection and the YKYY025 vaccine for lower respiratory tract diseases caused by respiratory syncytial virus, reflecting its expanding footprint in high-potential, unmet medical needs. Additionally, the company has experienced notable corporate changes including the acquisition of a 5.89% stake by a group of investors, signaling increased market confidence. Youcare continues to emphasize intelligent manufacturing, green production, and aligns its quality systems with global pharmaceutical standards to strengthen its competitive position. Youcare Pharmaceutical Group's business model spans R&D, manufacturing, and commercialization, targeting healthcare providers and patients in China and abroad. Its recent advancements in clinical-stage pipelines and strategic partnerships position it as a significant player in both the traditional and innovative pharmaceutical sectors within the rapidly evolving healthcare landscape in China and internationally. This description reflects Youcare Pharmaceutical Group Co., Ltd.'s comprehensive product offerings and significant recent company initiatives as of 2025.